September 22, 2020 | English | عربي
   Add to Twitter
 
Takeda Announces Results from Phase 3 Clinical Trial Evaluating NINLARO™ (ixazomib) in Newly Diagnosed Multiple Myeloma
− TOURMALINE-MM2 Data Presented Virtually at the Society of Hematologic Oncology (SOHO) Eighth Annual Meeting